Pfizer, Trump and tariffs Bourla

Pfizer's CEO says he's got a plan to deal with Trump's tariffs — move overseas drug manufacturing to the US
"I was expecting him probably to win. It was very big win," Pfizer's CEO Albert Bourla said of President Donald Trump's election victory.
Pfizer CEO says he's prepared to shift manufacturing to the U.S. amid tariff threats
CEO Albert Bourla said on Monday that the drugmaker could move some of its overseas manufacturing to its U.S. plants if necessary, as the Trump administration considers imposing tariffs on pharmaceuticals.
Pfizer could shift overseas production to US if Trump's pharma tariffs take hold, CEO says
As biopharma players continue to parse out what the second Trump administration means for the industry, Pfizer CEO Albert Bourla, Ph.D., outlined one potential response by his company if pharmaceut | Pfizer’s local manufacturing setup is already well positioned in the U.
Pfizer could use existing US manufacturing to counter potential tariff hit
By Christy Santhosh (Reuters) -Pfizer CEO Albert Bourla said on Monday the drugmaker might move overseas manufacturing to its existing plants in the United States, if required, as the Trump administration threatens numerous tariffs on imported goods.
Pfizer's Strategic Manufacturing Shift Amidst Tariff Threats
Pfizer CEO Albert Bourla announced the possibility of shifting overseas manufacturing to U.S. plants. This response is due to the Trump administration's tariff threats on imported goods. Bourla mentioned their U.
Pfizer may move outside manufacturing plants to US: CEO amid tariff threats
The US president has imposed a 10 per cent tariff across all Chinese imports into the US and proposed a 25 per cent levy on most goods from Mexico and Canada
Pfizer may soon move its overseas manufacturing to United States to counter potential tariff hit
Pfizer CEO Albert Bourla on Monday said that the company might move overseas manufacturing to its existing plants in the United States. The plan comes as the Trump administration
Pfizer could move outside manufacturing to the US, says CEO
(Reuters) -Pfizer CEO Albert Bourla said on Monday the drugmaker might move overseas manufacturing to its existing plants in the U.S., if required, as the Donald Trump administration threatens numerous tariffs on imported goods.
STAT7d
Pfizer CEO Albert Bourla inflicts injury on his company — and all of pharma
The hiring of a former top FDA official amplifies "revolving door" criticism at the worst possible time, STAT's Adam ...
Irish Examiner on MSN17h
Pfizer may bring some overseas manufacturing to US if required, says chief exec
If something happens, we will try to mitigate by transferring from manufacturing sites outside to manufacturing sites here' ...
FiercePharma11d
PhRMA leaders prepare to meet with Trump as new chair Albert Bourla espouses optimism
As the second Trump administration settles in, the U.S.' top pharmaceutical trade group is drafting its ambitions for the ...
STAT10d
An awkward moment for Pfizer’s Bourla in Washington
The future of the CDC’s vaccine advisory committee seems uncertain: A scheduled February meeting for the ACIP, which advises ...
Bisnow9h
Trump's Regulatory Rollback Hailed As Big Pharma Plans Expansions
Big Pharma executives feel optimistic about their industry’s trajectory under a second Donald Trump presidency, with regulation rollbacks and other changes likely to boost bottom lines for drugmakers, ...